Moderna, Inc. (MRNA) experienced a significant intraday surge, with shares soaring 6.94% during Thursday's trading session.

The stock's upward movement follows the company's recent Science Day event where it disclosed its in vivo CAR-T project mRNA-6007 targeting B-cell mediated autoimmune diseases, with plans to enter clinical trials next year. Moderna also showcased multiple pipeline assets including tumor vaccines, cancer prevention vaccines, and an AI-driven R&D platform, fueling market expectations for the company's transition from a single-product vaccine maker to a platform biotechnology company.

Additional catalysts include the unanimous 9-0 support from the FDA Vaccines and Related Biological Products Advisory Committee for Moderna's seasonal flu vaccine candidate mRNA-1010, with a final regulatory decision expected by August 5. These developments prompted analyst upgrades, with Piper Sandler raising its price target to $77 from $69 while maintaining an Overweight rating.